An interventional study of Auditory closed-loop stimulation and Sham stimulation in Major Depressive Disorder and Healthy, sponsored by Christoph Nissen. Recruiting at 1 site in Switzerland. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-23.
Sponsored by Christoph Nissen · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Depressive Disorder, Major with a site in Switzerland — 7 open to participants now, 8 under way, none of them phase 3. Depressive Disorder, Major · Switzerland.
Among the 30 studies in Depressive Disorder, Major with a site in Switzerland, this one is the 12th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2024, is one of 18 with no phase, and was the 23rd registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →7 of the 30 studies in Depressive Disorder, Major with a site in Switzerland are open now. Recruiting first, the newest first:
University of Bern · Sites in Switzerland
Ages 18–60 · Healthy volunteers
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 21+
University of Bern · Sites in Switzerland
Ages 20–75 · Healthy volunteers
University of Zurich · Sites in Switzerland
Ages 18–65
Andreas Walther · Sites in Switzerland
Ages 25–50 · Men only
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 30 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 60 across the 25 interventional studies, 190 across the 5 observational. Of the 18 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 30 have an industry lead sponsor. The 10 most frequent:
Christoph Nissen is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Christoph Nissen has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
1 of the studies in Depressive Disorder, Major with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059234University of BernThe Motor Activity - Subjective Energy (MASE) Project | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Depressive Disorder, Major with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Current first-line treatments for major depression (antidepressants and psychotherapy) show a long latency to response, and less than half of all patients experience full remission with optimized treatment, indicating the need for new developments. The aim of this study is to extend and further develop a longstanding line of research of using sleep neurophysiology as a 'window to the brain' and treatment development in major depression. Particularly, this project is designed to test the feasibility, efficacy and mechanisms of action of a new sleep-based treatment technology.
The planned study is a single-centre, doubled-blind, randomized, sham controlled, repeated measures within-subject (stimulation and sham) study including patients with major depression and healthy controls, across four sleep laboratory nights (adaptation, baseline, stimulation and sham in counterbalanced order). The investigators will test the primary hypothesis that auditory-closed loop suppression of slow wave sleep will improve depressive clinical symptomatology compared to sham stimulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with major depressive disorder according to ICD-10 criteria
Device: Auditory closed-loop stimulation · Device: Sham stimulation
Healthy controls
Device: Auditory closed-loop stimulation · Device: Sham stimulation
Auditory closed-loop suppression of slow wave sleep
No auditory stimulation
Montgomery Åsberg Depression Rating Scale
Measure of the severity of depressive symptomatology The scores range between 0 to 60. The higher the score, the more symptamology of depression the subjects presents.
Time frame: Up to three weeks
Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 24 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 24 months is below that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.